Mitochondrial DNA Abnormalities in Idiopathic Inflammatory Myopathies: Innate Immune Signaling and Therapeutic Prospects
International Journal of Molecular Sciences · 06.11.2026 · 27 (21) · 9949
DOI: 10.3390/ijms27219949 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.11.2026. Verfasst von Guanyuan Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China. Hauptthemen laut MEDLINE: DNA, Mitochondrial, Immunity, Innate, Myositis. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government Foundation of Excellent Clinical Medicine Talent Program of Hebei.
Abstract (Originalsprache)
Mitochondrial DNA (mtDNA) encodes essential components of oxidative phosphorylation and can stimulate innate immunity when released from mitochondria. Its genetic and immunological functions provide a rationale for investigating mtDNA abnormalities in idiopathic inflammatory myopathies (IIMs), where muscle dysfunction and inflammation coexist. Large-scale deletions and depletion have been documented in inclusion body myositis and polymyositis with mitochondrial pathology, while dermatomyositis studies reveal regional depletion and oxidative modifications in distinct biological compartments. These findings raise the possibility that mtDNA abnormalities contribute to both impaired mitochondrial function and inflammatory signaling. This review integrates subtype-specific findings with mechanistic studies of mtDNA release, DNA sensing, and inflammasome activation in IIM-related and non-IIM systems. It evaluates the evidence for mtDNA-based biomarkers and therapies targeting mitochondrial injury or downstream inflammation. The reported clinical benefits do not establish mtDNA-specific therapeutic effects. Defining how mitochondrial genome abnormalities and inflammatory signaling interact within each subtype is a priority for biomarker validation and therapeutic research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
- Hebei Medical University-National University of Ireland Galway Stem Cell Research Center, Hebei Medical University, Shijiazhuang 050017, China.
- Hebei International Joint Research Center on Rheumatic Diseases, Shijiazhuang 050000, China.
- Discipline of Physiology, School of Pharmacy & Medical Sciences, Human Biology Building, University of Galway, H91 W5P7 Galway, Ireland.
- Hebei Research Center for Stem Cell Medical Translational Engineering, Shijiazhuang 050017, China.
ORCID-Profile: Guanyuan Wang, Karl J A McCullagh, Aijing Liu
Förderung
- Government Foundation of Excellent Clinical Medicine Talent Program of Hebei
Zitieren
APA
Wang, G., Wang, Y., Wang, X., McCullagh, K. J. A., & Liu, A. (2026). Mitochondrial DNA Abnormalities in Idiopathic Inflammatory Myopathies: Innate Immune Signaling and Therapeutic Prospects. International Journal of Molecular Sciences, 27(21), 9949. https://doi.org/10.3390/ijms27219949
Vancouver
Wang G, Wang Y, Wang X, McCullagh KJA, Liu A. Mitochondrial DNA Abnormalities in Idiopathic Inflammatory Myopathies: Innate Immune Signaling and Therapeutic Prospects. International Journal of Molecular Sciences. 2026;27(21):9949. doi:10.3390/ijms27219949
BibTeX
@article{Wang2026,
author = {Wang, Guanyuan and Wang, Yurui and Wang, Xinran and McCullagh, Karl J A and Liu, Aijing},
title = {Mitochondrial DNA Abnormalities in Idiopathic Inflammatory Myopathies: Innate Immune Signaling and Therapeutic Prospects},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9949},
doi = {10.3390/ijms27219949}
}
EUVIMED